Arcturus Therapeutics Holdings Inc. (ARCT) vs Myriad Genetics, Inc. (MYGN)
A side-by-side comparison of Arcturus Therapeutics Holdings Inc. and Myriad Genetics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ARCT
Arcturus Therapeutics Holdings Inc.
$13.24HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT
MYGN
Myriad Genetics, Inc.
$4.33HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT
Total return — ARCT vs MYGN
growth of $100 · dividends reinvested · last 10yARCT -18.2% (-2.0%/yr)MYGN -77.8% (-14.0%/yr)ARCT compounded faster over this window
ARCT MYGN
ARCT vs MYGN: by the numbers
- •MYGN is the larger company ($409M vs $376M market cap).
- •Both run net losses; MYGN's is the smaller (-13.96% vs -391.90% net margin).
- •ARCT grew revenue faster over the past five years (22.30% vs 9.70% CAGR).
Metrics side by side
Valuation
| Metric | ARCT | MYGN |
|---|---|---|
| P/S ratio | 15.81 | 0.51 |
| P/B ratio | 2.19 | 1.34 |
Profitability
| Metric | ARCT | MYGN |
|---|---|---|
| Gross margin | 95.50% | 68.83% |
| Operating margin | -111.51% | -12.22% |
| Net margin | -391.90% | -13.96% |
| ROE | -54.29% | -37.05% |
| ROIC | -54.07% | -19.13% |
Growth (annualized)
| Metric | ARCT | MYGN |
|---|---|---|
| Revenue CAGR (5Y) | 22.30% | 9.70% |
| Total return CAGR (5Y) | -18.73% | -32.02% |
Frequently asked
- Which has grown faster, ARCT or MYGN?
- Over the past five years, ARCT grew revenue faster — ARCT at a 22.30% CAGR versus MYGN at 9.70%.
- How have ARCT and MYGN total returns compared?
- Over the past 10 years, ARCT delivered -2.54% and MYGN delivered -14.20% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Arcturus Therapeutics ROEMyriad Genetics ROEArcturus Therapeutics operating marginMyriad Genetics operating marginArcturus Therapeutics revenue growthMyriad Genetics revenue growthArcturus Therapeutics free cash flowMyriad Genetics free cash flow
Arcturus Therapeutics & Myriad Genetics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.